Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EZH2 | Q15910 | 9/20 | 0.68 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.49 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.47 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8738978 | 0.90 | EZH2 (0.69) | EZH2MEN1KMT2ASLC6A5L3MBTL1 | |
| SCHEMBL8738981 | 0.87 | EZH2 (0.65) | EZH2MEN1KMT2ASLC6A5L3MBTL1 | |
| SCHEMBL6121036 | 0.83 | EZH2 (0.78) | EZH2MEN1KMT2AL3MBTL1 | |
| SCHEMBL6120173 | 0.82 | EZH2 (0.77) | EZH2MEN1KMT2AMRGPRX4L3MBTL1 | |
| SCHEMBL8738147 | 0.82 | EZH2 (0.77) | EZH2MEN1KMT2AMRGPRX4L3MBTL1 | |
| SCHEMBL8738997 | 0.81 | EZH2 (1.00) | EZH2MEN1KMT2ASLC6A5 | |
| SCHEMBL8738593 | 0.81 | EZH2 (0.59) | EZH2MEN1KMT2AL3MBTL1 | |
| SCHEMBL8738629 | 0.81 | EZH2 (0.74) | EZH2MEN1KMT2AL3MBTL1 | |
| SCHEMBL8739021 | 0.80 | EZH2 (0.55) | EZH2MAPK14SLC6A5 | |
| SCHEMBL8738206 | 0.80 | EZH2 (0.73) | EZH2MEN1KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012068589-A2 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS (US) | 2012-05-24 | — | — | WO | disclosed |